Therefore, the function gain that accompanies p53 mutation not only reverses cell cycle inhibition of wild-type p53 but also induces chemoresistance to gemcitabine in pancreatic adenocarcinoma cells. This evidence concerns the gene TP53 and pancreatic adenocarcinoma.